The litany of big-ticket deals involving antibody-drug conjugates shows no sign of ending. In the latest recitation, Bristol-Myers Squibb is paying $800 million upfront for rights to a HER3-directed ...

This should count as a hack: making music from a thing that should not sing. In this case, [SIROJU] is tickling the ivories with a Brushless DC motor, or BLDC.  To listen to a performance, jump to ...